Terns Pharmaceuticals, Inc.

NasdaqGS:TERN Voorraadrapport

Marktkapitalisatie: US$491.8m

Terns Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Amy Burroughs

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOless than a year
Eigendom CEOn/a
Management gemiddelde ambtstermijnless than a year
Gemiddelde ambtstermijn bestuur3.9yrs

Recente managementupdates

Recent updates

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Oct 21

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 25

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 10

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Aug 18
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

May 03
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Jan 12
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Sep 29
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Jun 06
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Feb 21
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Terns Pharmaceuticals: The Easy Money Has Been Made

Sep 20

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Aug 08

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Jun 14
Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Mar 16
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Nov 24
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Aug 24
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Jun 14

CEO

Amy Burroughs (54 yo)

less than a year

Tenure

Ms. Amy L. Burroughs, M.B.A., serves as CEO & Director at Terns Pharmaceuticals, Inc. from February 07, 2024. She serves as Independent Director of Tenaya Therapeutics, Inc. since December 2022. She had be...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mark Vignola
CFO & Treasurer4.3yrsUS$3.14m0.027%
$ 134.3k
Amy Burroughs
CEO & Directorless than a yeargeen gegevensgeen gegevens
Elona Kogan
Chief Legal Officerless than a yeargeen gegevensgeen gegevens
Jeffrey Jasper
Senior Vice President of Research2.8yrsgeen gegevensgeen gegevens
Emil Kuriakose
Chief Medical Officer1.5yrsgeen gegevensgeen gegevens
Melita Jung
Chief Business Officerless than a yeargeen gegevensgeen gegevens
Scott Harris
Chief Development Officerless than a yeargeen gegevensgeen gegevens
Debra Sieminski
Senior Vice President of Medical Affairsless than a yeargeen gegevensgeen gegevens
David Strauss
VP of Finance & Controllerless than a yeargeen gegevensgeen gegevens

0.8yrs

Gemiddelde duur

46.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TERN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Amy Burroughs
CEO & Directorless than a yeargeen gegevensgeen gegevens
Carl Gordon
Independent Director6.1yrsUS$298.99k0%
$ 0
Jeffrey Kindler
Independent Director3.9yrsUS$304.99k0%
$ 0
Heather Turner
Directorno datageen gegevensgeen gegevens
Hongbo Lu
Independent Director4.6yrsUS$299.99k0.56%
$ 2.8m
Joe Shih
Member of Scientific Advisorno datageen gegevensgeen gegevens
David Fellows
Independent Chairman3.9yrsUS$340.15k0%
$ 0
Stephen A. Harrison
Member of Scientific Advisorno datageen gegevensgeen gegevens
Juan Lopez-Telavera
Member of Scientific Advisorno datageen gegevensgeen gegevens
Radhika Tripuraneni
Independent Director2.3yrsUS$303.06k0%
$ 0
Michael Charlton
Member of Scientific Advisorno datageen gegevensgeen gegevens
Jill Quigley
Independent Director3.9yrsUS$480.49k0.018%
$ 86.9k

3.9yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TERN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).